Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Clin Pract ; 75(10): e14581, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34185386

RESUMEN

OBJECTIVE: De Quervain tenosynovitis is the most common cause of lateral wrist pain. The diagnosis can be made with the Finkelstein test when pain is provoked with wrist ulnar deviation. Conservative treatment including rest, non-steroidal anti-inflammatory medication and physical therapy is applied first, then there may be a need for corticosteroid injections, and in resistant cases, surgery. The aim of this study was to evaluate the effectiveness of neural therapy (NT) on pain and hand functions in patients with De Quervain tenosynovitis. METHODS: A total of 36 patients admitted between May 2019 and March 2020 were randomly assigned to neural therapy (NT) and control groups. Hand rest and thumb spica splint were applied to all the patients, and NT interventions to the NT group only. A visual analogue scale (VAS) and the Duruöz Hand index (DHI) were used to measure pain and functionality at baseline, then at 1 and 12 months after the end of the treatment. RESULTS: The NT and control groups both showed improvements in VAS and DHI scores at 1 and 12 months compared with baseline (P < .001) according to within group comparisons. The VAS scores were significantly lower at both 1 and 12 months compared with baseline in the NT group (P < .001, P = .002 respectively). The DHI scores were lower in the NT group at 1 month (P = .009), and at 12 months there was no significant difference between the two groups (P = .252). No adverse effects were seen in any patient. CONCLUSION: NT seems to be effective in reducing pain and improving hand functions in patients with De Quervain tenosynovitis.


Asunto(s)
Enfermedad de De Quervain , Tenosinovitis , Anestésicos Locales , Enfermedad de De Quervain/tratamiento farmacológico , Humanos , Dolor , Estudios Prospectivos
2.
Complement Med Res ; : 1-5, 2020 Apr 21.
Artículo en Inglés | MEDLINE | ID: mdl-32316009

RESUMEN

BACKGROUND: In this study, we aimed to assess the effect of neural therapy in the prevention of post-tubal syndrome, which is the combination of dysmenorrhea, bloating, dyspareunia, heavy menstrual bleeding, chronic vaginitis, and cystitis, after elective bilateral tubal ligation with modified Pomeroy technique. MATERIAL AND METHODS: In total, 113 patients who have undergone bilateral tubal ligation with modified Pomeroy technique between January 2016 and December 2018 in our clinic have been included. Postoperatively, patients were divided into two groups. One group received neural therapy (n = 52), and the other group did not receive neural therapy (control group, n = 61). Both groups were evaluated in terms of preoperative and postoperative symptoms. One year after surgery, patients' pain levels were evaluated using visual analog scale (VAS). RESULTS: When both groups were compared in terms of symptoms, dysmenorrhea, dyspareunia, bloating, frequency of vaginitis, and cystitis per year and pain perception using VAS, the symptoms were significantly less in the neural therapy group. However, there was no difference between the groups in terms of the amount of menstrual bleeding. CONCLUSIONS: Patients who received neural therapy showed less pain symptoms (dysmenorrhea and dyspareunia), and their VAS scores were lower when compared to the control group. Thus, we concluded that neural therapy is effective in the treatment of post-tubal syndrome.

3.
J Back Musculoskelet Rehabil ; 31(6): 1105-1110, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30010101

RESUMEN

BACKGROUND: The aim of this study was to explore the effect of neural therapy on pain and functionality in patients with low back pain due to piriformis syndrome. It also aimed to find out any possible links between the clinical changes and demographic features. METHOD: One hundred and two patients were randomly divided into two groups (neural therapy and control). All patients were given stretching exercises for the piriformis muscle. The patients in the neural therapy group additionally received 6 sessions of neural therapy. The visual analog scale (VAS) and Oswestry Disability Index (ODI) were noted before and after the treatment in both groups. RESULTS: The VAS and ODI improved in both groups. However, improvement of the VAS and ODI scores were more obvious in the neural therapy group. The changes of VAS and ODI values did not show any correlations with the demographic features. CONCLUSION: After the neural therapy, the patients with low back pain due to piriformis syndrome may have improvement in both pain and functioning.


Asunto(s)
Evaluación de la Discapacidad , Terapia por Ejercicio/métodos , Síndrome del Músculo Piriforme/rehabilitación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndrome del Músculo Piriforme/fisiopatología , Estudios Prospectivos , Resultado del Tratamiento , Escala Visual Analógica
4.
Neurourol Urodyn ; 36(7): 1832-1838, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28084625

RESUMEN

AIMS: Many agents and treatments are used in the treatment of neurogenic detrusor overactivity (NDO) in MS patients, but no study has been conducted on the use of peripheric lidocaine (neural therapy-NT) on MS patients. We evaluated the effects of local administration of lidocaine on NDO in Multiple Sclerosis (MS) patients. METHODS: For each patient local anesthetic lidocaine was injected at each session. Sessions were held once a week for 5 weeks. At each session, Th 10-L1, urogenital segment intradermal injections, Frankenhauser, and sacral epidural injections were given. The patients had clinical and urodynamic assessment 1 month before and 3, 9, and 12 months after NT. In addition, multiple sclerosis quality of life inventory (MSQL-54) and bladder control scale (BLCS) was performed for patients. RESULTS: Twenty-eight patients were included in the study (8 males, 20 females). The patients' average age was 31.7 ± 8.1 years. The injection therapy significantly improved volume at first involuntary bladder contraction (FCV), maximal detrusor pression during filling (P det. max.), maximal cystometric bladder capacity (MCC) after 3 months. Also, the MSQL-54 and BLCS scores were improved with treatment. However, these improvements reached a maximum 3 months after treatment, but from the 9 month a regression was seen in the parameters, and after 12 months the findings were seen to be slightly above their basal levels. CONCLUSIONS: These results suggest that NDO treatment in MS patients could be an effective treatment which is easy and has very few side effects, and is cost effective.


Asunto(s)
Anestésicos Locales/uso terapéutico , Lidocaína/uso terapéutico , Vejiga Urinaria Neurogénica/tratamiento farmacológico , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Adulto , Femenino , Humanos , Inyecciones Epidurales , Inyecciones Intradérmicas , Masculino , Esclerosis Múltiple/complicaciones , Calidad de Vida , Estudios Retrospectivos , Resultado del Tratamiento , Vejiga Urinaria Neurogénica/complicaciones , Vejiga Urinaria Hiperactiva/etiología , Urodinámica/efectos de los fármacos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA